EcoDrugPlus

Cytochrome P450 26a1

Ensembl ID : ENSEEEG00000015370
Gene Symbol: LOC113584635
4 Cross references
195 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSEEEG00000019757
Gene Symbol: LOC113591420
3 Cross references
586 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSEEEG00000019636
Gene Symbol: LOC113591419
4 Cross references
602 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSEEEG00000000016
Gene Symbol: LOC113575193
4 Cross references
563 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSEEEG00000010006
Gene Symbol: CYP19A1
4 Cross references
246 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSEEEG00000005634
Gene Symbol: DGAT1A
2 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSEEEG00000017831
Gene Symbol: DGAT1B
2 Cross references
188 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSEEEG00000000951
Gene Symbol: DHODH
4 Cross references
173 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSEEEG00000011391
Gene Symbol: DPYD
4 Cross references
214 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSEEEG00000007093
Gene Symbol: DDR2
4 Cross references
205 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSEEEG00000012860
Gene Symbol: DRD1
4 Cross references
189 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSEEEG00000003691
Gene Symbol: DRD1B
4 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).